As more and more research is being conducted on the now legal cannabinoid, cannabidiol is soon expected to be used to treat a plethora of diseases and conditions. Two new issued patents from March of 2021 explain the use of CBD for treating diseases caused by Pseudomonas aeruginosa as well as ADD/ADHD. Pseudomonas infections are most likely to occur in hospitalized patients with the patent specifying treating head and neck surgical-related conditions, skin and soft tissue infections, as well as wound infections. As for treating ADHD with the cannabinoid, the invention specifies a composition containing at least one other additive from the group consisting of passion flower, a root extract from a valerian species, ashwagandha, and spikenard. The effective amount of CBD is between 2-20% of the total composition weight.
Research is still ongoing for CBD’s medicinal properties. Pharmotech SA is the owner of the patent for treating Pseudomonas with CBD and will have rights to exclude others for 20 years from the filing date as will the independent inventor for the method of treating ADD/ADHD. Stay up to date with patent developments in Cannabis and sign up for the Cannabis Patent Forecast®. Start your free trial today!
